News headlines about Conatus Pharmaceuticals (NASDAQ:CNAT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.0445490030165 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
CNAT traded down $0.13 during trading on Friday, reaching $4.05. 130,575 shares of the company’s stock were exchanged, compared to its average volume of 244,170. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.35 and a current ratio of 2.35. Conatus Pharmaceuticals has a fifty-two week low of $3.22 and a fifty-two week high of $7.95. The firm has a market capitalization of $126.00 million, a PE ratio of -6.64 and a beta of 1.23.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. The company had revenue of $8.77 million for the quarter, compared to analysts’ expectations of $9.06 million. Conatus Pharmaceuticals had a negative net margin of 48.46% and a negative return on equity of 69.68%. equities analysts forecast that Conatus Pharmaceuticals will post -0.61 EPS for the current year.
A number of analysts have commented on CNAT shares. Oppenheimer set a $14.00 target price on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 3rd. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. Finally, ValuEngine raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Conatus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $12.50.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.